Evidence map›Paper›PMID 23340550›Full record

ArticleThe Pediatric infectious disease journal2013

Reducing the frequency of acute otitis media by individualized care.

Michael E Pichichero, Janet R Casey, Anthony Almudevar

Abstract read
In one paragraph

Article in The Pediatric infectious disease journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Plasma metabolomics in infancy reveals early signatures of a stringently-defined otitis-prone phenotype.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  2. Article
  3. Article
  4. New insights into the treatment of acute otitis media.Expert review of anti-infective therapy · 2023
    Review
  5. Observational
  6. Article
  7. Article
  8. Synchrony in serum antibody response to conserved proteins ofHuman vaccines & immunotherapeutics · 2020
    Article
  9. Panel 3: Genomics, precision medicine and targeted therapies.International journal of pediatric otorhinolaryngology · 2020
    Review
  10. Impaired Proinflammatory Response in Stringently Defined Otitis-prone Children During Viral Upper Respiratory Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Panel 3: Genetics and Precision Medicine of Otitis Media.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2017
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Michael E PichicheroCenter for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester NY 14621, USA. Michael.pichichero@rochestergeneral.org
Janet R Casey
Anthony Almudevar
Legacy International · USRochester General Hospital · US

Funding

NTHi Immunity in Young ChildrenR01DC008671 · NIDCD · UNIVERSITY OF ROCHESTER · PI PICHICHERO, MICHAEL E · 2007 to 2016
$5.8M
NIDCD NIH HHS R01 DC008671NIDCD NIH HHS R01DC08671
6 · The paper itself

Abstract

objectiveWe sought to determine if use of more stringent diagnostic criteria for acute otitis media (AOM) than currently advocated by the American Academy of Pediatrics, tympanocentesis and pathogen-specific antibiotic treatment (individualized care) would result in reducing the incidence of recurrent AOM and consequent tympanostomy tube surgery.

methodsA 5-year longitudinal, prospective study in Rochester, NY, was conducted from July 2006 to July 2011 involving 254 individualized care children. When this individualized care group developed symptoms of AOM, strict diagnostic criteria were applied and a tympanocentesis was performed. Pathogen resistance to empiric high-dose amoxicillin/clavulanate (80 mg/kg of amoxicillin component) caused a change in antibiotic to an optimized choice. Legacy controls (n = 208) were diagnosed with the same diagnostic criteria by the same physicians as the individualized care group and received the same empiric amoxicillin/clavulanate (80 mg/kg of amoxicillin component) but no tympanocentesis or change in antibiotic. Community control children (n = 1020) were diagnosed according to current American Academy of Pediatrics guidelines and treated with high-dose amoxicillin (80 mg/kg) without tympanocentesis as guideline recommended.

results5.9% of children of the individualized care group compared with 14.4% of Legacy controls and 27.3% of community controls became otitis prone, defined as 3 episodes of AOM within a 6-month time span or 4 AOM episodes within a 12-month time span (P < 0.0001). 2.4% of the individualized care group compared with 6.3% of Legacy controls, and 14.8% of community controls received tympanostomy tubes (P < 0.0001).

conclusionsIndividualized care of AOM significantly reduces the frequency of AOM and tympanostomy tube surgery. Use of strict diagnostic criteria for AOM and empiric antibiotic treatment using evidence-based knowledge of circulating otopathogens and their antimicrobial susceptibility profile also produces improved outcomes.

Indexed as

AmoxicillinAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsChild, PreschoolFemaleHumansInfantKaplan-Meier EstimateMaleMiddle Ear VentilationNew YorkOtitis MediaPrecision MedicineProspective StudiesRisk FactorsSeasonsAmoxicillinAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial Agents

Identifiers

PMID23340550
PMCPMC3681924
OpenAlexW1988554633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.